EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Higher Colonic Tissue Drug Concentrations of Subcutaneous Compared to Intravenous Administration of Infliximab Therapy in Patients With Inflammatory Bowel Disease

X Roblin, S Nancey, K Papamichael, F Mechi, J Ouvrier-Buffet, A L Charlois, A S Peaucelle, L Bastide, A A Berger, M Barrau, A S Cheifetz, G Duru und 1 weitere

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70207 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von X Roblin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France. Hauptthemen laut MEDLINE: Infliximab, Colon, Gastrointestinal Agents, Colitis, Ulcerative. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intestinal tissue levels of infliximab (IFX) in patients with inflammatory bowel disease (IBD) treated with subcutaneous (SC) therapy have not been previously assessed.

Objective

To compare serum and colonic tissue IFX concentrations in IBD patients receiving SC versus intravenous (IV) IFX.

Methods

This observational cross‐sectional study included IBD patients on stable SC or IV IFX maintenance therapy undergoing routine follow‐up colonoscopy. Clinical activity required elevated CDAI or Mayo score plus ≥ 1 biomarker (fecal calprotectin > 250 μg/g or CRP > 5 mg/L). Blood samples and two colonic biopsies were collected for serum and tissue IFX measurements.

Results

Thirty‐five patients were included. Serum and tissue IFX concentrations were significantly higher in the SC versus IV group (22 μg/mL vs. 9 μg/mL, p < 0.001; 25 μg/g vs. 10 μg/g, p = 0.002). Serum and colonic tissue IFX levels were positively correlated in both cohorts (IV: r = 0.42; p = 0.014; SC: r = 0.43; p = 0.001). Colonic tissue IFX concentrations were higher in patients with mild–moderate endoscopic activity than in those without active disease ( p < 0.001). Serum and colonic tissue IFX levels both predicted sustained clinical remission, with optimal thresholds of 14.5 μg/mL ( p = 0.015) and 17 μg/g ( p < 0.005), respectively. Colonic tissue IFX showed higher predictive accuracy (AUROC 0.82, p = 0.01) than serum (AUROC 0.76, p = 0.045).

Conclusions

SC IFX achieved significantly higher serum and colonic tissue concentrations than IV IFX. Colonic tissue IFX levels demonstrated superior clinical relevance and may support future tissue‐based therapeutic drug monitoring strategies in IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabColonGastrointestinal AgentsColitis, UlcerativeHumansFemaleMaleCross-Sectional StudiesAdultInjections, SubcutaneousColonoscopyMiddle AgedBiopsyAdministration, IntravenousLeukocyte L1 Antigen ComplexBiomarkersIntestinal Mucosa

Substanzen

InfliximabGastrointestinal AgentsLeukocyte L1 Antigen ComplexBiomarkers

Autor:innen und Institutionen

  • Department of Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France.
  • Department of Gastroenterology, Lyon-Sud Hospital, Hospices Civils de Lyon, University Claude Bernard Lyon 1 and CIRI (Centre International de Recherche en Infectiologie), INSERM U1111, Lyon, France.
  • Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Centre, Boston, Massachusetts, USA.
  • Immunology Laboratory/iBioThera, CIC1408, University Hospital of Saint-Etienne, Saint-Etienne, France.
  • CIRI, Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-Etienne, Saint-Etienne, France.

Zitieren

APA

Roblin, X., Nancey, S., Papamichael, K., Mechi, F., Ouvrier-Buffet, J., Charlois, A. L., Peaucelle, A. S., Bastide, L., Berger, A. A., Barrau, M., Cheifetz, A. S., Duru, G., & Paul, S. (2026). Higher Colonic Tissue Drug Concentrations of Subcutaneous Compared to Intravenous Administration of Infliximab Therapy in Patients With Inflammatory Bowel Disease. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70207

Vancouver

Roblin X, Nancey S, Papamichael K, Mechi F, Ouvrier-Buffet J, Charlois AL, et al. Higher Colonic Tissue Drug Concentrations of Subcutaneous Compared to Intravenous Administration of Infliximab Therapy in Patients With Inflammatory Bowel Disease. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70207

BibTeX
@article{Roblin2026,
  author = {Roblin, X and Nancey, S and Papamichael, K and Mechi, F and Ouvrier-Buffet, J and Charlois, A L and Peaucelle, A S and Bastide, L and Berger, A A and Barrau, M and Cheifetz, A S and Duru, G and Paul, S},
  title = {Higher Colonic Tissue Drug Concentrations of Subcutaneous Compared to Intravenous Administration of Infliximab Therapy in Patients With Inflammatory Bowel Disease},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70207}
}
Kostenlos starten →